Filter
719
Text search:
drug
formulations
Featured
Recommendations
91
New Publications
210
Language
Document type
No document type
399
Guidelines
150
Studies & Reports
94
Manuals
37
Training Material
13
Strategic & Response Plan
10
Fact sheets
9
Situation Updates
2
Resource Platforms
2
Brochures
1
App
1
Infographics
1
Countries / Regions
India
51
Kenya
28
Global
23
Ethiopia
15
South Africa
15
Malawi
15
Western and Central Europe
12
Africa
12
Tanzania
11
Uganda
10
Nepal
10
Bangladesh
10
Sierra Leone
9
Nigeria
8
Zimbabwe
8
Zambia
8
Namibia
8
Liberia
7
Ghana
7
Philippines
7
Rwanda
7
Myanmar / Burma
7
South–East Asia Region
6
Latin America and the Carribbean
6
Eastern Europe
6
Cameroon
4
Cambodia
4
Eswatini/ Swaziland
4
Senegal
3
Haiti
3
Syria
3
Benin
3
Botswana
3
Burkina Faso
2
Indonesia
2
East and Southern Africa
2
Middle East and North Africa
2
Russia
2
Congo, Democratic Republic of
1
Mali
1
Côte d’Ivoire / Ivory Coast
1
Niger
1
Pakistan
1
South Sudan
1
Afghanistan
1
Thailand
1
Malaysia
1
Mozambique
1
Argentina
1
Peru
1
Brazil
1
Ukraine
1
Colombia
1
Bolivia
1
Madagascar
1
Lesotho
1
Sri Lanka
1
Chile
1
Yemen
1
Western Pacific Region
1
Eastern Europe and Central Asia
1
Paraguay
1
Bhutan
1
Venezuela
1
Congo-Brazzaville
1
Tajikistan
1
Australia
1
Georgia
1
North America
1
France
1
Authors & Publishers
Publication Years
Category
Countries
258
Clinical Guidelines
129
Women & Child Health
33
Public Health
32
Key Resources
19
Pharmacy & Technologies
15
Capacity Building
9
Toolboxes
HIV
105
TB
92
Pharmacy
63
AMR
40
Mental Health
32
NTDs
32
COVID-19
15
NCDs
15
Malaria
13
Rapid Response
9
Caregiver
9
Ebola & Marburg
8
Refugee
5
Planetary Health
5
Disability
4
Conflict
4
2.0 Rapid Response
4
Cholera
3
Polio
3
Health Financing Toolbox
3
Zika
2
Specific Hazards
2
Global Health Education
2
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with
...
Previous advocacy efforts have achieved tangible goals in terms garnering political commitments
to increase financing for TB—as seen at the 2018 UN High-Level Meeting on TB. The challenge
now is to ensure that these commitments are actually met within a global biomedical research
ecosystem that
...
Towards a world free of tuberculosis
6th edition. The HIV epidemic Namibia is gradually being brouhgt under countrol as demonstrated by results in the preliminary report of Namibia Population-Based HIV Impact Assessment (NAMPHIA), a cross-sectional household-based survey that was conducted in 2017. Currently, it is estimated that about
...
Each year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to
prevent, diagnose, control or cure neglected diseases in low- and middle-income countries, making it the go
...
2nd edition. This second edition builds on the experience of more than 10 years of SMC deployment, and reflects changes introduced in the WHO guidelines for malaria, 3 June 2022. The goal of this publication is to share these best practices to improve SMC implementation, coverage, and monitoring and
...
This document by Medicines for Malaria Venture (MMV) highlights the significant burden of malaria on children worldwide, emphasizing the need for effective prevention, diagnosis, and treatment strategies. It reviews current challenges and progress in combating pediatric malaria, advocating for conti
...
Clinical Pharmacology: Advances and Applications, 2025:17 29–47
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN
...
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Tuberculosis (TB) remains a significant global health challenge, with an estimated annual death rate of approximately one per 100,000 people in countries with low TB prevalence. Rapid reductions in TB cases and deaths worldwide depend on research breakthroughs, including the development of new vac
...